Tartan

Tartan Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation lipid nanoparticle (LNP) delivery systems for genetic medicines. The company's technology, originating from research at Carnegie Mellon University, utilizes high-throughput screening to identify novel ionizable lipids capable of delivering nucleic acid payloads beyond the liver. By optimizing the chemical structure of LNPs, Tartan aims to enable precise, extra-hepatic targeting for mRNA, siRNA, and gene editing therapies. Their platform is designed to overcome the current limitations of delivery, broadening the clinical application of genetic medicines to treat a diverse array of complex and rare diseases. The company is backed by prominent life science venture capital firms and is positioned as a leader in the evolving field of non-viral delivery technologies.